Post-Transplant Cytoxan
Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning (RIC) With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 56 patients (estimated)
- Sponsors
- University of Minnesota - Masonic Cancer Center
- Tags
- Xanthine Oxidase Inhibitor
- Trial Type
- Treatment
- Last Update
- 2 weeks ago
- SparkCures ID
- 1629
- NCT Identifier
- NCT05805605
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.